Stoke Therapeutics Poised for Growth with Anticipated Earnings and Breakthrough in Dravet Syndrome Treatment
Stoke Therapeutics Inc. is poised for growth as it prepares to release its Q2 2025 earnings report, with promising developments in its clinical pipeline and a potential game-changing treatment for Dravet syndrome on the horizon.
3 minutes to read